Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples